Perseis Therapeutics (Perseis) is a drug development company with a focus on novel monoclonal antibody based therapeutics for the treatment of cancer. The antibodies are inhibitors of factors involved in controlling cancer cell growth, migration and resistance to chemotherapy drugs. These antibodies are of particular interest as potential anti-cancer therapeutics and re-sensitisation agents. Results to date strengthen the clinical correlation between both Growth Hormone and two TFF (treefoil factors) proteins with Breast Cancer.

In April 2009 the Breast Cancer Research Trust invested $1.2m (25%) in Perseis as seed investors with Neuren Pharmaceuticals Limited.

In May 2011 we had a major breakthrough whereby 3 key Antibodies have shown to strongly inhibit breast (and stomach) cancers in the laboratory.  Each has the potential to stop breast cancer in its tracks, in a type that affects the majority of sufferers (up to 68%).

Antibodies of this particular type (fully human) typically result in shorter and less expensive drug development, and have a reduced risk of sufferers’ reactions to residual murine proteins in the finished drug product – all of which means a CURE faster and with less side effects.        

We have already begun discussions with global pharmaceutical companies about the next steps based on results from the in vivo studies. They recognize the significance of the breakthrough and have shown strong interest in pursuing it.

Therefore we would like to request your support of finding a cure for breast cancer, to please join the effort to accelerate our search and click on the link below to make a donation to this crucial research.